Introduction Although dabigatran, an oral direct thrombin inhibitor, does not require routine
monitoring, high plasma concentration of dabigatran (PDC) at trough level is shown to be a …

Routine laboratory monitoring is currently not recommended in patients receiving dabigatran
despite its considerable variation in plasma concentration. However, in certain clinical …

Dabigatran is a direct thrombin inhibitor that has been approved for preventing stroke in
patients with atrial fibrillation. In this study, we aimed to assess the associations between the …

This study aimed to evaluate the variability of dabigatran plasma concentration and the
association with clinical events in Chinese patients treated with dabigatran etexilate (DE) for …

Introduction Dabigatran etexilate, a direct oral anti-coagulation agent, is used in the
prevention of thromboembolism in patients with non-valvular atrial fibrillation (NVAF) …

Ways to monitor dabigatran etexilate (DE) therapy would be useful in certain situations.
Functional assays such as aPTT or Hemoclot® Thrombin Inhibitor (HTI) have been …

Aims In patients with atrial fibrillation prescribed dabigatran, the aim was to examine the
correlation between plasma dabigatran concentrations and the three screening coagulation …

Background Knowledge of anticoagulation status during dabigatran therapy may be
desirable in certain clinical situations. Objective To determine the coagulation tests that are …

Douxfils et al. are concerned about the wide range of trough dabigatran levels among
individuals reported in our cohort (< 30 ng mL À1 to 510 ng mL À1)[1], citing their ex vivo …

We read with interest the recent prospective observational study by Chan et al.[1] The
authors aimed to investigate the interpatient and intrapatient variabilities in dabigatran …